Emergence of resistance during mupirocin treatment: Is it a problem in clinical practice?

Journal of Chemotherapy

Volumn 11, Issue 5, 1999, Pages 331-337

  Henkel, T ^a   Finlay, J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Mupirocin; Nasal colonization; Resistance; Skin infections; Staphylococcus aureus

Indexed keywords

PSEUDOMONIC ACID;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; HUMAN; LONG TERM CARE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SKIN INFECTION; TREATMENT OUTCOME;

EID: 0032705343     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.5.331     Document Type: Article

References (41)

1. Utrup LJ, Finlay JE, Rittenhouse SF, Poupard JA. Comparison of mupirocin susceptibility of nasal and non-nasal Staphylococcus aureus isolates. Diag Microbiol Infect Dis 1994; 20: 171-174.
2. Cookson BD, Lacey RW, Noble WC, Reeves DS, Wise R, Redhead RJ. Mupirocin-resistant Staphylococcus aureus [letter]. Lancet 1990; 335: 1095-1096.
3. Gu JW, Briones F, Fang W. Susceptibility of 1309 nasal isolates of Staphylococcus aureus from hospital personnel in the United States to 21 antibiotics. Presented at the 91st General Meeting of the American Society for Microbiology 1991: A97.
4. Martin de Nicolas MM, Vindel A, Torrellas A. In vitro activity of mupirocin and 11 other antibiotics against 1500 Spanish clinical isolates of S. aureus causing hospital infections from 1979-1992. Presented at the 18th International Congress of Chemotherapy 1993: A891.
5. Chatfield CA, O'Neill WA, Cooke RP et al. Mupirocin-resistant Staphylococcus aureus in a specialist school population. J Hosp Infect 1994; 26: 273-278.
6. Rahman M, Noble WC, Cookson B. Mupirocin-resistant Staphylococcus aureus. Lancet 1987; 2: 387.
7. Boelaert JR, Van Landuyt HW, Godard CA et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant 1993; 8: 235-239.
8. Prescribing Information. SmithKline Beecham Pharmaceuticals, 1995.
9. Kraus SJ, Eron LJ, Bottenfield GW, Drehobl MA, Bushnell WD, Cupo MA. Mupirocin cream is as effective as oral cephalexin in the treatment of secondarily infected wounds. J Fam Pract 1998; 47: 429-433.
10. Sutherland R, Boon RJ, Griffin KE, Masters PJ, Slocombe B, White AR. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother 1985; 27: 495-498.
11. Hughes J, Mellows G. Interaction of pseudomonic acid A with Escherichia coli Isoleucyl-tRNA synthetase. Biochem J 1980; 191: 209-219.
12. Farmer TH, Gilbart J, Elson SW. Biochemical basis of mupirocin resistance in strains of Staphylococcus aureus. J Antimicrob Chemother 1992; 30: 587-596.
13. Cookson BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 1998; 41: 11-18.
14. Capobianco JO, Doran CC, Goldman RC. Mechanism of mupirocin transport into sensitive and resistant bacteria. Antimicrob Agents Chemother 1989; 33: 156-163.
15. Gilbart J, Perry CR, Slocombe B. High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases. Antimicrob Agents Chemother 1993; 37: 32-38.
16. Hodgson JE, Curnock SP, Dyke KGH, Morris R, Sylvester DR, Gross MS. Molecular characterization of the gene encoding high-level mupirocin resistance in Staphylococcus aureus J2870. Antimicrob Agents Chemother 1994; 38: 1205-1208.
17. Smith GE, Kennedy CT. Staphylococcus aureus resistant to mupirocin [letter]. J Antimicrob Chemother 1988; 21: 141-142.
18. Ramsey MA, Zarins LT, Bradley SF, Kauffman CA, Morton TM. Identification of the mupirocin resistance gene on the staphylococcal chromosome: evidence to support IS-mediated recombination. Presented at the 94th General Meeting of the American Society for Microbiology, 1994: A97.
19. Morton TM, Johnston JL, Patterson J, Archer GL. Characterization of a conjugative staphylococcal mupirocin resistance plasmid. Antimicrob Agents Chemother 1995; 39: 1272-1280.
20. Ramsey MA, Bradley SF, Kauffman CA, Morton TM. Identification of chromosomal location of mupA gene, encoding low-level mupirocin resistance in staphyloccal isolates. Antimicrob Agents Chemother 1996, 40: 2820-2823.
21. Udo EE, Pearman JW, Grubb WB. Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1994; 26: 157-165.
22. Eltringham I. Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 1997; 35: 1-8.
23. Marples RR, Speller DCE, Cookson BD. Prevalence of mupirocin resistance in Staphylococcus aureus. J Hosp Infect 1995; 29: 153-161.
24. Boelaert JR, Van Landuyt HW, Gordts BZ, De Baere YA, Messer SA, Herwaldt LA. Nasal and cutaneous carriage of Staphylococcus aureus in hemodialysis patients: the effect of nasal mupirocin. Infect Control Hosp Epidemiol 1996; 17: 809-816.
25. Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of mupirocin ointment. Infect Control Hosp Epidemiol 1996; 17: 811-813.
26. Netto dos Santos KR, de Souza Fonseca L, Gontijo Filho PP. Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian University Hospitals. Infect Control Hosp Epidemiol 1996; 17: 813-816.
27. Kauffman CA, Terpenning MS, He X et al. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment. Am J Med 1993; 94: 371-378.
28. Layton MC, Patterson JE. Mupirocin resistance among consecutive isolates of oxacillin-resistant and borderline oxacillin-resistant Staphylococcus aureus at a university hospital. Antimicrob Agents Chemother 1994; 38: 1664-1667.
29. Finlay JE, Miller LA, Poupard JA. Interpretive criteria for testing susceptibility of staphylococci to mupirocin. Antimicrob Agents Chemother 1997; 41: 1137-1139.
30. Van der Auwera P, Couvreur ML, Grenier P et al. In vitro susceptibility of 1324 strains of Staphylococcus aureus isolated during a nationwide epidemiological study in 1991-92. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1993: 967.
31. Moorhouse E, Fenelon L, Hone R, Smyth E, McGahon J, Dillon M. Staphylococcus aureus sensitivity to various antibiotics - a national survey in Ireland 1993. Ir J Med Sci 1996; 165: 40-43.
32. Andrews J, Ashby J, Jevons G, Lines N, Wise R. Antimicrobial resistance in Gram-positive pathogens isolated in the UK between October 1996 and January 1997. J Antimicrob Chemother 1999; 43: 689695.
33. Schmitz F-J, Lindenlauf E, Hofmann B, Fluit AdC, Verhoef J, Heinz H-P, Jones ME. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother 1998; 42: 489-495.
34. Moy JA, Caldwell Brown D, Lin AN, Pappa KA, Carter DM. Mupirocin-resistant Staphylococcus aureus after long-term treatment of patients with epidermolysis bullosa. J Am Acad Dermatol 1990; 22: 893-895.
35. Boelaert JR, de Baere Y, Deruyter M, Gordts B, van Landuyt H, Herwaldt L. Long-term evaluation of chemoprophylaxis of S. aureus bacteraemia in haemodialysis by nasal mupirocin. Presented at the 20th International Congress of Chemotherapy, 1997: 2228.
36. Kluytmans JAJW, Manders M-J, van Bommel E, Verbrugh H. Elimination of nasal carriage of Staphylococcus aureus in hemodialysis patients. Infect Control Hosp Epidemiol 1996; 17: 793-797.
37. Kluytmans JAJW, Mouton JW, VandenBergh MFQ et al. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 1996; 17: 780-785.
38. Doebbeling BN. Nasal and hand carriage of Staphylococcus aureus in healthcare workers. J Chemother 1994; 6 (suppl 2): 11-17.
39. Doebbeling BN, Breneman DL, Neu HC et al. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. Clin Infect Dis 1993; 17: 466-474.
40. Redhead RJ, Lamb YJ, Rowsell RB. The efficacy of calcium mupirocin in the eradication of nasal Staphylococcus aureus carriage. Br J Clin Prac 1991; 45: 252-254.
41. Hudson IRB. The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: a review of recent experience. J Hosp Infect 1994; 27: 81-98.